CASTRATION RESISTANT PROSTATIC CANCER
Clinical trials for CASTRATION RESISTANT PROSTATIC CANCER explained in plain language.
Never miss a new study
Get alerted when new CASTRATION RESISTANT PROSTATIC CANCER trials appear
Sign up with your email to follow new studies for CASTRATION RESISTANT PROSTATIC CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Hard-to-Treat prostate cancer: JANX007 enters human trials
Disease control Recruiting nowThis early-stage study tests a new drug, JANX007, in men with metastatic castration-resistant prostate cancer that has worsened after other treatments. The main goals are to check safety and find the right dose. About 272 participants will receive the drug to see if it can help c…
Matched conditions: CASTRATION RESISTANT PROSTATIC CANCER
Phase: PHASE1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated May 26, 2026 05:56 UTC
-
New drug MGC026 enters human trials for advanced cancers
Disease control Recruiting nowThis study tests a new drug, MGC026, in 250 adults with advanced solid tumors that have not responded to other treatments. The goal is to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive the drug by IV and are closely monitored f…
Matched conditions: CASTRATION RESISTANT PROSTATIC CANCER
Phase: PHASE1 • Sponsor: MacroGenics • Aim: Disease control
Last updated May 26, 2026 05:56 UTC
-
Heartburn drug could boost chemo in tough prostate cancer
Disease control Recruiting nowThis study tests whether adding omeprazole (a common heartburn medicine) to standard chemotherapy can help shrink tumors or slow cancer growth in men with advanced prostate cancer that has stopped responding to other treatments. About 50 men will receive either cabazitaxel or doc…
Matched conditions: CASTRATION RESISTANT PROSTATIC CANCER
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated May 26, 2026 05:49 UTC
-
New hope for Hard-to-Treat prostate cancer: experimental drug combo enters human trials
Disease control Recruiting nowThis study tests a new drug called ifinatamab deruxtecan (I-DXd), given alone or with other treatments, for men with metastatic castration-resistant prostate cancer (mCRPC) that has stopped responding to standard hormone therapy. About 360 participants will join to find safe dose…
Matched conditions: CASTRATION RESISTANT PROSTATIC CANCER
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 05:45 UTC